

20 22 ANNUAL REPORT




BIOQUÉBEC

The Quebec Bio-Industries and Life Sciences Business Network

“ Nothing is lost, nothing is created,
everything is transformed. ”

| Antoine Lavoisier



A WORD FROM THE CHAIR OF THE BOARD OF DIRECTORS

While the entire planet was on pause, or at least in slow motion, during the pandemic's much-too-long duration, the life sciences sector was operating at top speed.

Everyone's initiatives and contributions produced a very high level of innovation and accelerated drug and vaccine discovery and manufacturing processes without compromising patient health. New business and operational practices emerged and quickly became standards. Our sector went through an accelerated (r)evolution that carried over into 2022. Many have distinguished themselves in this wild race for vaccines, therapeutic antibodies, drugs, and diagnostic tools. Still, the real impact of all these efforts will not be fully apparent for another decade or so. In the short term, a new generation of vaccines and immunotherapies for various indications has already appeared in the market, spurred by the giant steps we have collectively taken over the past two years. In the medium to long term, biotechnology, combined with artificial intelligence, quantum computing, and genomics, will create a complete human health revolution.

The pandemic also allowed the general public to experience science in real-time, to better understand the ins and outs of scientific research, and to be introduced to the passionate people behind it. However, since everything happened very quickly, it also led to some rather dubious and wild theories. As an association representing the biotechnology sector and the people who work in it, we must continue sharing information with our fellow citizens, be even more clear in explaining what our work is all about, and let them know about upcoming innovations that will improve everyone's health and quality of life. The pandemic left us with an opportunity to communicate we must seize!

BIOQuébec also changed in 2022 and will continue to evolve to serve its members better and make government authorities aware of the sector's issues of concern. In 2022, we continued to offer a significant number of webinars, and we reintroduced in-person activities to once again facilitate discussions on topics of interest for our community and issues that concern our sector. These include the release of the results of the study on the integration of Quebec innovations into the healthcare system, hosting a panel on gene therapy during the Effervescence event, Quebec CROs' mission to Boston, not to mention our team's continued involvement throughout the year on major policy issues such as changes to the PMPRB regulations, the tabling and implementation of Bill 96 (use of French), and the tabling of Bill 19 (brief - access to data) which became Bill 3 following the election. Under the leadership of a dynamic board of directors, a new team took over in the fall and continued to speak on behalf of Quebec's life sciences sector's businesses. We will maintain this strong momentum in 2023 and provide you with the opportunity to interact with a fresh and energetic team that is committed to representing all BIOQuébec members!

"Nothing is lost, nothing is created, everything is transformed." This famous quote by Antoine Lavoisier, the father of modern chemistry, is an accurate reflection of 2022. Our sector is experiencing a transformation, and BIOQuébec will remain positioned to represent you and share in your greatest victories!



FRÉDÉRIC LEDUC, CHAIR



THANKS to Our Annual Partners for Their Support

Your unwavering support allows
biotechnology and life sciences to thrive!



TABLE OF CONTENTS

BIOQUÉBEC'S DNA	6
Committees and Governance	7
HIGHLIGHTS	8
Agent of Change – Current Issues	10
INDUSTRY VOICE	13
BIOQuébec's Publications	14
Members' Profile and Network Activities	16
Member Services – The Power of the Network	19
Overview of Members' Benefits	21
Savings and Operational Advantages	22
FINANCIAL SUMMARY	23
Statement of Operations	23
Balance Sheet	24
2022-2024 Strategic Plan	25

BIOQuébec's DNA

BIOQuébec is an association that serves its members. While it highlights issues of concern, offers solutions, fosters networking and business development, and showcases its businesses by sharing their promising discoveries and many successes with the public, BIOQuébec's primary role is to represent its member companies' interests before government officials and the general public by promoting their contribution to society. Its members' participation makes it a dynamic network of innovative companies offering unique opportunities for exposure and growth.

MISSION

BIOQuébec is committed to supporting Québec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and commercialization, and is dedicated to improving everyone's health and quality of life.

VISION

To position Québec, on an international scale, as an undeniable key player in the biotechnology and life sciences field.

THE BIOQuébec TEAM

Through its various iterations and transformations, the BIOQuébec team has remained your reliable and dedicated partner, your point of reference in the life sciences sector, and, above all, your attentive and responsive team.

In 2022, this committed and evolving team was represented in the field by:



ANIE PERRAULT

Executive Director
| January – August 2022



STÉPHANIE BILODEAU

Project Manager, Analyst
| January – October 2022



MARIE-PIERRE MALTAIS

Project Coordinator, Member Services
and Benefits
| January – September 2022



EMMANUELLE TOUSSAINT

Executive Director
| August – December 2022



GAËLLE BRIDON

Communications Manager and
Analyst-Advisor
| October – current



JOSÉE TREMBLAY

Administration and
Events Coordinator
| September – current

COMMITTEES AND GOVERNANCE

To carry out BIOQuébec's mission, the members of its Board of Directors held five regular meetings, three extraordinary meetings, and one annual general meeting. In addition, audit committee members held three meetings while the governance committee held four meetings during the year.

EXECUTIVE COMMITTEE

Frédéric Leduc, Chair	Chief Scientific Officer, EVAH
Yves Roy, Vice-Chair	President, Corealis Pharma
Véronique Bougie, Vice-Chair	Chief Operating Officer, SemaThera Inc.
Suzie Talbot, Administrator	President and CEO, Diex Recherche
Luc Tanguay, Treasurer	Corporate Director

ADMINISTRATORS

Marie-Ève Côté	Lawyer, Partner, ROBIC
François Laflamme	Senior Director, Public Affairs and Government Relations, IQVIA Canada
François-Thomas Michaud	CEO, Feldan Therapeutics
Carl Viel	President and CEO, Québec International
Nadine Beauger	President and CEO, IRICoR
Jean-Maurice Plourde	Economist (retired)
Nicolas Petit	Vice-President of Commercial Operations, Medicago
Mounia Azzi	Vice-President, Corporate Development, adMare BioInnovations
Ranya El-Masri	Vice-President, Head of Government Affairs and Market Access, GSK Canada
Nadia di Chiara	Director, Private Equity and Impact Investing, Life Sciences, Fonds de Solidarité FTQ
Sarah Jenna	Co-Founder and CEO, My Intelligent Machines

AUDIT COMMITTEE

Luc Tanguay Chair
Véronique Bougie
Nicolas Petit
François-Thomas Michaud

GOVERNANCE COMMITTEE

Carl Viel Chair
Ranya El-Masri
Mounia Azzi
Nadine Beauger
Marie-Ève Côté

HIGHLIGHTS 2022

What a busy year 2022 was, with many events and wonderful opportunities that allowed BIOQuébec to support the interests of the industry and its members. Since it can be difficult to remember them all, here is a summary:

JANUARY

- **Café Croissant with Bloom Burton & Co** featuring the financial year in review and summary of investments made in the sector and of its vitality.
- **Café Croissant with Angés Québec**, a leader in the province's early-stage investment industry, on angels' role in the development of Quebec's innovative biotech.

FEBRUARY

- **Café Croissant with IRICoR** on its strategic role in supporting the transformation of therapeutic solutions from research to commercialization, and on Epiteopea's history.
- **Virtual conference** hosted in collaboration with the CQIB on launching a start-up, during which seasoned entrepreneurs shared their journey and tips on what to do and what to avoid.

MARCH

- **Participated in the Quebec government's closed** session on the 2022-2023 budget and statement to members on the planned investments in research, innovation, and life sciences. [Read the internal statement here](#) (in French only).
- **Submitted the survey** and began collecting data for the updated study on Quebec CROs.
- **Café Croissant with lawyers from Fasken Martineau DuMoulin LLP** who were directly involved in the PMPRB's new guidelines on the impacts, consequences, and other issues following the Court of Appeal of Quebec's judgement.
- **Supporting partner** of Women in Bio's Excellence in Canadian Board Governance program, which aims to increase diversity on the life sciences industry's boards of directors. "Tipping the Balance - Driving Gender Parity on Life Sciences Corporate Boards" virtual event presented in collaboration with Women in Bio.

AVRIL

- **Café Croissant with Levoya** on the benefits of transferring a human health research project to animal health.
- **Presentation of the study report** - Integration of innovations in the healthcare system by Anie Perrault, Bernard Lachapelle, economist, and Alain Dubuc from Groupe JBL.

MAY

- **Quebec CROs mission to Boston:** BIOQuébec and Investissement Québec led a mission featuring eleven CRO companies who were members of BIOQuébec to Boston to meet with MassBio executives, participate in MassBio's State of Possible Conference, speak with investors during pre-arranged meetings, and enjoy many networking opportunities. [Find out more here.](#)
- **Participated in the closed** session in preparation for the 2022-2025 Québec Life Sciences Strategy designed to support and foster the growth of Quebec's life sciences ecosystem. Statement on this strategy's potential for developing this sector's human capital and new businesses.
- **2022 Annual General Meeting**
 - Presentation by Repare Therapeutics' Lloyd Segal on the current state of Quebec's biotechnology industry.
 - Speech by Pierre Fitzgibbon, Minister of Economy and Innovation, and inauguration of adMare BioInnovations' new facility.
 - Networking cocktail reception - Celebrating BIOQuébec's 30th anniversary.

JUNE

- **Entertaining and well-received** pivot for the 1st Annual Golf Classic held in Bromont: rainy weather forced organizers to turn the tournament into a skill-testing event featuring circus games. This adaptability allowed the 105 participants to enjoy themselves and make great connections.
- **Part of the Quebec delegation's** trip to the Bio International Convention in San Diego and co-organizer of a panel discussion attended by over 100 people, presented in conjunction with the Biotech City to address why so many companies have chosen to have their biomanufacturing operations in Quebec.
- **Appointment of the board of directors' new chair**, Frédéric Leduc.

JULY

- **Letter to Premier Legault** about Bill 96, which aims to promote the widespread use of the French language, highlighting the detrimental effects it could have on the life sciences industry and its workers around the world.

AUGUST

- **Announcement** by the board of directors that Emmanuelle Toussaint was named Executive Director. [Find out more here.](#)
- **Constructive meeting** with the U.S. ambassador to Canada, the U.S. Deputy Assistant Secretary, the Consul General in Montréal, and the Manufacturiers et Exportateurs du Québec's CEO during which subjects such as opportunities for women in the life sciences sector, the need for a diversified supply chain, and the collaboration between governments and private industry were discussed. In addition to those issues, WIB and BioTalent Canada's initiatives, CROs' potential, and limitations relating to immigration were also addressed.

SEPTEMBER

- **Welcomed and triumphant return** of the in-person fall cocktail reception and speed-meeting supper, a lively and memorable evening for life sciences industry members and stakeholders to renew relationships and make new connections.
- **Attended BIONation 2022** in Ottawa and participated in a discussion on the importance of innovation, collaborations, and investments in both life sciences and the biotechnology sector.

OCTOBER

- **The BIOQuébec team** expands with the arrival of Josée Tremblay and Gaëlle Bridon! These two individuals' commitment and dedication level towards the organization and its members has been clear from Day One. What great team spirit!
- **Café Croissant with CARTaGENE** on the potential to accelerate health research and reduce costs thanks to its biobank data and samples from 43,000 Quebecers.

NOVEMBER

- **Awarded the Prix innovation en sciences de la vie** life sciences award to Innodal. Created by BIOQuébec, this award was presented in partnership with Innovative Medicines Canada during the ADRIQ's 32nd gala. [For more details, click here.](#)
- **Annual holiday cocktail** reception, attended by 200 guests and organized by BIOQuébec in conjunction with the Biotech City, and launch of the Cercles d'excellence impact leadership and sustainable management program for industry members. [Learn more here](#) (in French only).

DECEMBER

- **Partner in the Quebec City** Healthcare Industry Forum's 2022 edition and participated in the conference on female diversity in leadership and innovation, which focused on the ecosystem's companies' social responsibility and how they can benefit from supporting the inclusion of women. [Find out more here](#) (in French only).
- **Provided guidance** on how to be named to a board of directors during Women In Bio - Greater Montréal's life sciences speakers series on ECBG (Excellence in Canadian Board Governance).



AGENT OF CHANGE

– CURRENT ISSUES

Through its many actions and activities, BIOQuébec continuously works to address the key issues affecting life sciences and biotechnology organizations. Through its dedication to its members, its responsiveness, its ability to adapt to changing situations, and its leadership, BIOQuébec's team brings a pragmatic approach and supports real-world action. Several major issues directly impacting the operational reality of the sector's businesses and organizations have transitioned from one phase to the next with the help of BIOQuébec, who has ensured that its members' perspective has been clearly expressed to provincial and federal government representatives.

Awareness of Industry Issues: Information Initiatives About the Sector's and BIOQuébec's Members' Operational Needs

Bill 96 on the Use of the French Language

Letter to Premier Legault to make the government aware of the potentially detrimental effects of Bill 96 on Quebec's life sciences sector and the protection it should receive. To be competitive internationally, as outlined in the Québec Life Sciences Strategy's objectives, companies in this sector must recruit experts, partners, investors, and influential people from - more often than not - outside Quebec and around the world. This legislation, which aims to promote the widespread use of the French language, creates significant challenges for these companies when major industry stakeholders find themselves sitting at the same table, with only English as their common language.

Bill 19 to Foster Access to Health Data

Introduced in late 2021, this Bill contained ambitious proposals to support access to and use of health data in Quebec. Rewritten as Bill 3 a year later, it promotes the responsible exploitation and administration of health data between healthcare network institutions. In collaboration with our colleagues from MedTech, IMC, Montréal InVivo, Québec International, and the Sherbrooke Innopole, BIOQuébec devoted a lot of time to this issue in 2022. Several meetings with Mr. Dubé's office as well as with officials responsible for this Bill were held, and a memorandum was submitted to the office of the Minister in charge containing discussion points and recommendations to support access for research purposes and make the health network more competitive and productive, while also ensuring appropriate management of this data by healthcare and social services organizations.

Results of the Study on the Integration of Innovations Into the Healthcare System

Initiating this report positions BIOQuébec as a life sciences stakeholder interested in the entire ecosystem, both upstream and downstream of the innovation chain, and focused on the optimal development of biopharmaceutical research in Quebec.

The study's results, exclusively presented to BIOQuébec's members, revealed the framework for action chosen by BIOQuébec and its partners to better support biosciences and open a constructive dialogue with government stakeholders. These actions aim to improve the environment for integrating innovations in Quebec and, as such, foster cooperation between stakeholders while supporting the development of our biopharmaceutical companies. .

Number of meetings held in relation to the study on the integration of innovations:


4: INESSS

4: Bureau de l'Innovation

2: Ministry of Economy and Innovation

Several: staff from the offices of the ministers of Health and of Economy and Innovation

[Head here to learn more.](#)



Update to the Québec Life Sciences Strategy (QLSS)

After many consultations and meetings to which BIOQuébec and several of its members contributed, the tabling of the second draft of the Québec Life Sciences Strategy was cause for celebration. BIOQuébec participated in the closed session during which the Strategy was tabled. It then issued a press release on the Strategy's potential to address the issues and priorities identified by its members during the consultations, and to support future human capital development and the growth of start-ups in this sector.

Launching Medicines in Canada


Moderated a panel discussion during Life Sciences Ontario's "Is Canada Losing Its Status as a Priority Medicine Launch Country?" webinar.

Release of a joint statement with Life Sciences Ontario outlining that although Canada has been recognized as a priority country for launching new medicines for the last twenty years, changes to pharmaceutical policies have undermined the country's ability to maintain this status.

[To learn more and to view the report, click here.](#)

Changes to the Patented Medicines Prices Review Board's Guidelines (PMPRB)

The proposed changes to the PMPRB's patented medicines guidelines were as much of an issue of concern in 2022 as in 2021. Along with its partners and other provincial life sciences associations, BIOQuébec argued the industry's position to the federal government on multiple occasions. [For more information about this issue](#) (in French only).



- **In February 2022**, the Court of Appeal of Quebec unanimously declared that these changes were partially invalid.
- **In March**, BIOQuébec, BIOTECanada, and IMC met with Health Canada to discuss the changes to the price control regulations and suggest further discussions to find a balanced solution.
- **Meanwhile**, BIOQuébec hosted a webinar for its members, featuring lawyers from Fasken Martineau DuMoulin LLP who were directly involved in the case, on the impacts, consequences, and other issues following the Court of Appeal of Quebec's judgement.




- **During** the Quebec federation of chambers of commerce's political meeting event, which took place on November 21 with the Honourable Jean-Yves Duclos, federal Minister of Health, in attendance, Executive Director Emmanuelle Toussaint reiterated that innovation in the sector is fundamental and that we need to ensure that innovations are not restricted by control measures, even though those may be recommended well-intentionally. [Find more information here.](#)
- **In December 2022**, BIOQuébec, Montréal InVivo, and Sherbrooke Innopole sent a letter asking the PMPRB to delay the effective date of the new guidelines, the provisions of which went against the judicial rulings on price control issued earlier in the year. [Read the letter here.](#)

INDUSTRY VOICE

The biotechnology and life sciences network's audience is one experiencing constant transformation and growth. In 2022, BIOQuébec continued carrying out its mandate of informing and promoting by using its digital platforms to create relevant content and share news about the industry and its members, which all benefited from this increased exposure. The network shared noteworthy information through its newsletter (which can be accessed by the general public) and its monthly *Infoactualités* news bulletin (which is available to BIOQuébec members only). As a result, its members' and partners' perspectives reach a wider audience.

DIGITAL PRESENCE

SOCIAL NETWORKS



663 posts
6,879 followers
+ 304,100 impressions
7% engagement rate

NEWSLETTERS AND NEWS BULLETIN



Close to 89,000 emails
1,340 subscribers

WEBSITE www.bioquebec.com



+ 23,700 unique visitors
+ 69,000 pages viewed

BIOQuébec is active on the following social networks:



In addition to sending out monthly e-mails summarizing the highlights, BIOQuébec has opted to share news about the subjects and issues that directly affect its network members. In 2022, BIOQuébec's members received e-mails on many topics, including:

- The CRO's mission to Boston
- The Court of Appeal of Quebec's decision on the PMPRB
- The launch and the results of the study on the integration of innovations into the healthcare system
- BioTalent Canada's new wage subsidy program's features
- Bill 96's impact on life sciences companies
- Montréal InVivo's *Compétences PME* productivity program for SMEs
- The option of contributing to the *La Presse* newspaper's special feature on life sciences

Mass mailings were used to continue the *Café Croissant* webinar tradition. In 2022, eight of these unifying events were held for members to learn more about a variety of topics and current issues; an average of sixty participants attended each one.

BIOQuébec's PUBLICATIONS

Study Report: “A Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy” – April 2022

“The innovations generated by Quebec’s biopharmaceutical industry must be integrated into our healthcare system, not only so that patients can benefit from them, but also to allow businesses to develop fully and create wealth here in Quebec.”

— Anie Perrault, Executive Director, BIOQuébec

While Quebec has a rich history and vibrant tradition of biopharmaceutical research and development, some members have experienced or are currently experiencing challenges integrating their innovations into Quebec’s system. BIOQuébec mandated Alain Dubuc, a renowned economist, and Bernard Lachapelle, President of Groupe JBL, to measure the integration rate of Quebec innovations into the healthcare system. They started by discovering that no data existed on the subject. Therefore, this study’s first contribution is to provide such data for the first time. Its second is to highlight that no clear definition of a Quebec biopharmaceutical innovation existed. So, we had to create one. [The results of our study](#) enabled us to suggest new courses of action for Quebec’s biopharmaceutical innovations to access the healthcare system and support the growth of our companies.

Study on CROs: A Pillar in Drug Development (work on the current report in progress)

Contract research organizations (CROs) are an integral part of the innovation chain, as they support biopharmaceutical companies through all phases of developing a new drug, vaccine, or medical device. Given their crucial role and economic importance, BIOQuébec and CATALIS, with financial support from the Ministry of Economy and Innovation, conducted a study of Quebec’s CROs to establish a profile of the sector and measure its evolution, strengths, and needs. Of the eighty-one CROs operating in Quebec, fifty-three companies responded to the survey. The study report will be released in 2023.

BIOQuébec's PUBLICATIONS

IN THE MEDIA

Biotechnology Week Press Review

For nineteen years, National Biotechnology Week has increased awareness about its vital role and global potential while promoting the sector to political representatives, opinion leaders, and the general public.

In 2022, in addition to the *La Presse* newspaper's [special edition on the sector](#) (in French only), innovative Quebec biotechs and members of BIOQuébec were featured on social media during the entire week. Its website also dedicated [a page](#) (in French only) to various areas of expertise, namely oncology, artificial intelligence, rare diseases, and innovative technologies.

This special edition shed light on the sector's issues, including integrating innovations and financing for start-up companies. Nevertheless, the outlook for the industry is good:



“The governments support us. In Quebec alone, the Québec strategy to support research and investment in innovation was launched last year. We can see that the sector is a priority.”

– Emmanuelle Toussaint, Executive Director, BIOQuébec

Other Media Appearances

1 Print advertorial about BIOQuébec in Insights Magazine. To learn more, [go to page 56 of the magazine](#).

1 Editorial in the November 25th edition of BioLAB Business entitled “Innovation Is the Foundation for Improving Healthcare,” featuring several members of the network. [Click here to learn more](#).

MEMBERS' PROFILE AND NETWORK ACTIVITIES

MEMBERS' PROFILE

Being a BIOQuébec member means...

Having access to key ecosystem events and advantageous networking activities


Having access to credible and relevant information about the sector

Having access to preferred services offered through partnerships (discounts on products, equipment, and services)

Being part of an exceptional network, unlike any other in Quebec, known for its ability to proactively represent its members

In 2022, BIOQuébec had 172 members: 66% which were associated with biotechs, CROs, pharmas, or drug formulation or manufacturing companies, 16% which offered services, financing, or support, and 17% which were connected to incubators or the academic sector.

Percentage of members according to their line of business



“As we emerge from the pandemic, Quebec’s life sciences ecosystem has a great opportunity to accentuate its evolution, and BIOQuébec will be there to support its members in meeting challenges and fostering their growth.”

— Frédéric Leduc, Chair, BIOQuébec

BIOQUÉBEC MEMBER ORGANIZATIONS IN 2022

BIOTECH, CONTRACT RESEARCH, PHARMA, FORMULATION, MANUFACTURING

- AbbVie Corporation
- AbCellera Biologics Inc.
- Acasti Pharma
- Affinité Instruments
- Alexion Pharma Canada Corp.
- Altus Formulation
- Amgen Canada
- ANANDA Devices
- Angany inc.
- AstraZeneca Canada Inc.
- AxCell Labs
- Azenta Life Sciences
- Azenta Life Sciences Canada, Inc
- Azitra Inc.
- Banook Group
- Bausch Health, Canada inc.
- BELLUS Health Inc.
- BendaRx Corp
- Biodextris
- Biotwin
- CIRION BioPharma Recherche inc.
- Congruence Therapeutics
- CURA Therapeutics
- DalCor Pharmaceuticals Canada Inc.
- Defence Therapeutics inc.
- Diex Recherche Sherbrooke
- Dispersa Inc.
- Divocco
- Domain Thérapeutiques NA Inc.
- Eli Lilly Canada inc.
- Emballage Spectrum Pharma
- EndoParagon inc
- eNUVIO inc.
- EVAH corp.
- ExCellThera Inc.
- Exeptise Inc.
- Feldan Therapeutics
- Find Therapeutics
- Giiant Pharma Inc.
- Glycovax Pharma Inc.
- Groupe Parima
- GSK
- HDAX Therapeutics
- Horizon Therapeutics Canada
- ILS Pharma Inc
- IMEKA Solutions inc.
- Immugenia Inc.
- Immune Biosolutions Inc.
- Immunovaccine Technologies Inc. (IMV)
- Incyte Biosciences Canada Corporation
- Ingenew BioPharma Inc.
- IniXium inc
- Inversago Pharma Inc.
- Invitrozyme Inc.
- ITR Laboratories Canada Inc.
- Ivano Bioscience
- Janssen inc.
- Jenthera Thérapeutiques
- Keyrus Life Science Canada
- KisoJi Biotechnology Inc.
- Laboratoire Bionatus Pharmacognosique Inc.
- Laboratoire Innodal
- Laboratoires Odan Ltée
- Laurent Pharmaceuticals inc.
- LFAnt Medical
- Medesis Pharma SA
- Medicago inc.
- Medpharmgene
- Mispro Biotech Services inc
- Modelis Inc.
- Modulari-T Biosciences
- Molecular Forecaster
- My Intelligent Machines (MIMS)
- NMX Research and Solutions Inc.
- Novartis Pharma Canada inc.
- NuChem Sciences
- Oligo Médic Inc.
- Oncodesign inc.
- Opalia
- Ovensa Innovations inc.
- Paraza Pharma inc.
- PCI Pharma Services Inc.
- Pfizer Canada inc.
- Pharma in silica inc.
- PhenoSwitch Bioscience Inc.
- PhInc Modeling
- Pink GenomiX
- Precision for Medicine
- Raspberry Scientific Inc.
- Repare Therapeutics
- RNA Technologies & Therapeutics
- Roche Diagnostics
- Ropack Pharma Solutions
- Saguario Technologies
- SemaThera inc.
- SmokePond Biologics
- Société TALLC Inc.
- Synthèse AptoChem inc.
- Synucure Thérapeutiques inc.
- Targa Biomédical inc.
- Tatum Bioscience Inc.
- Teva Canada Innovation
- Thérapeutiques Thryv
- Theratechnologies inc.
- Trepso Therapeutics Inc.
- Triple Hair
- Valence Discovery
- Vantage BioTrials Inc.
- Ventus Therapeutics
- VINEx

BIOQUÉBEC MEMBER ORGANIZATIONS IN 2022

GOVERNMENT ORGANIZATIONS, UNIVERSITIES, VALORIZATION CORPORATIONS OR OTHER NPOs

- Axelys
- Biocluster ECOGENE-21
- C3I - Le Centre de commercialisation de l'immunothérapie du cancer
- Centre de recherche du CHU de Québec
- Centre National en Électrochimie et en Technologies Environnementales (CNETE)
- CERASP
- Cité de la Biotech | Ville de Laval
- Conseil de formation pharmaceutique continue
- Conseil National de recherches Canada (CNRC)
- CQDM - Consortium de recherche biopharmaceutique
- District 3 | Université Concordia
- Exactis Innovation
- Fonds de recherche du Québec - Société et Culture (FRQSC)
- Génome Québec
- Institut de Cardiologie de Montréal- Montreal Health Innovations Coordinating Center (MHICC)
- Institut de recherche du Centre universitaire de santé McGill (IR-CUSM)
- Institut de recherche en immunologie et en oncologie de l'Université de Montréal (IRIC)
- Institut de recherches cliniques de Montréal (IRCM)
- Investissement Québec
- IRICoR
- Laboratoire national de biologie expérimentale (LNBE | INRS)
- Médicaments Novateurs Canada
- Pharmabio Développement
- Q-CROC
- Québec International
- RI-MUHC
- Sherbrooke Innopole
- TransBIOTech - Centre de recherche et de transfert en biotechnologies
- Université de Sherbrooke

ANNUAL PARTNERS

- adMare Bioinnovations
- BioTalent Canada
- Corealis Pharma inc.
- Montréal InVivo
- ThermoFisher Scientific

PLATINUM PARTNER

- Laboratoires Charles River Montréal ULC

SUPPORT SERVICES

- AmorChem II Ventures inc.
- ArchiMed SAS
- Banque Nationale secteur Sciences de la vie et Santé
- Canadian Advanced Therapies Training Institute (CATTI)
- CASTL Canada
- CBRE Limitée | Services consultatifs et transactionnels
- Centre québécois d'innovation en biotechnologie (CQIB)
- CF Services Analytiques
- CMC-Rx Consultancy
- Conseillers en gestion et informatique CGI Inc.
- Consultation Pharm-Asset Inc
- Fasken Martineau DuMoulin S.E.N.C.R.L., s.r.l.
- Fonds CTI Sciences de la Vie
- Fonds de Solidarité FTQ
- Fonds Theodorus IV
- HarveyCorp
- IQVIA Solutions Canada inc.
- Lavery, de Billy, s.e.n.c.r.l.
- LEVOYA inc.
- Luc Tanguay
- Lumira Ventures
- OROKOM
- Recherche Continuum Research
- Robic S.E.N.C.R.L.
- SAGE Assurances et rentes collectives
- TACT Intelligence-conseil Inc.
- Vézina Assurances Inc.



MEMBER SERVICES

THE POWER OF THE NETWORK

ASSOCIATIVE LIFE

Through its agility, adaptability, and responsiveness, BIOQuébec reflects the spirit of its members and, like them, works in an ever-changing sector. Just like the flow of water in various settings, its energy constantly evolves and manifests itself in its rich associative life. In 2022, several community-building events greatly contributed to the passion for life sciences in Quebec:

EFFERVESCENCE 2022

A signature event for Quebec's life sciences, Effervescence is an opportunity to share ideas and promote the sector's innovations. BIOQuébec and Génome Québec hosted a panel discussion on developments in gene therapy.



ANNUAL GENERAL MEETING

The 2022 AGM was followed by a presentation by Lloyd Segal, a speech by Minister Fitzgibbon, and the inauguration of adMare BioInnovations' new facility. BIOQuébec's 30th anniversary was celebrated during the networking cocktail reception - a great way to end such a full day.



GOLF CLASSIC

Although the very first edition of the Golf Classic didn't go as planned due to rain, the fun activities and rich interactions won't soon be forgotten by the many who attended.



FALL COCKTAIL RECEPTION AND NETWORKING SUPPER

The welcomed in-person return of this annual reception was an extraordinary networking opportunity.



CHRISTMAS COCKTAIL RECEPTION

BIOQuébec and the Biotech City, which organized this must-attend annual event, were thrilled to see many partners, colleagues, and friends throughout the evening.



2022 ADRIQ INNOVATIONS AWARDS GALA

This annual gala is one of the most prestigious events highlighting innovation across all of Quebec's economic sectors. This year, the Innovation award in life sciences, created by BIOQuébec and awarded in partnership with Innovative Medicines Canada, was won by Innodal. This network member focuses on innovating with antimicrobial solutions. The winners and more than 500 attendees enjoyed this unique opportunity for increased exposure and to benefit from media coverage of the event.



MEMBER SERVICES THE POWER OF THE NETWORK

NETWORKING

Through various events and by making connections between interested parties, BIOQuébec creates opportunities for its members to engage, share information, and establish business ties with the ecosystem's stakeholders within the province and around the world.



INTERACTIVE MAP

Created in collaboration with Montréal International, with the support of Corealis Pharma, Fisher Scientific, and Charles River, this interactive map lets users search for and find life sciences organizations by region, line of business, and type of operation or specialty.



INTERASSOCIATION AND INTERNATIONAL AGREEMENTS

BIOQuébec opens discussion and business development pathways with national associations such as Innovative Medicines Canada, Medtech Canada, and BIOTECCanada.

BIOQuébec fosters connection and collaboration opportunities for its members through international agreements such as:



MassBio in the U.S. – This partnership allows BIOQuébec members to attend this large American association's events at the MassBio member rate, be invited to participate in certain financing opportunities, submit applications to the MassBioDrive accelerator program, access various professional development forums without charge, and enjoy discounts offered by its partners.



BioForward in the U.S. – The agreement helps to outline a reciprocal relationship which fosters networking and helps create transborder partnerships between the members of both organizations.



The Coolest Hotspot, a Quebec Life Sciences and Health Technologies Business Community initiative - BIOQuébec continued its strategic and administrative support of this project, which provides increased exposure for Quebec companies' successes and assets on the international stage.

OVERVIEW OF MEMBERS' BENEFITS

MEMBER SERVICES – BENEFITS

VIRTUAL EVENTS

In 2022, several virtual events were offered exclusively and without charge to BIOQuébec members, such as:

- A webinar on launching a life sciences start-up (what to do and what to avoid) held in partnership with the CQIB
- “Tipping the Balance – Driving Gender Parity on Life Sciences Corporate Boards” webinar, hosted in partnership with Women In Bio and held on International Women’s Day
- “Is Canada Losing Its Status as a Priority Medicine Launch Country?” webinar, moderated by BIOQuébec and presented by Life Sciences Ontario
- Webinar introducing the report on the study on integrating Quebec innovations titled “A Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy”



THE CAFÉ CROISSANT SERIES

The *Café Croissant* webinar series' tradition (in French only) which BIOQuébec launched at the beginning of the pandemic as a virtual way for members to connect and discuss important subjects and issues, expanded even further in 2022.



This Year's Guests and Topics

- *Café Croissant* with **Bloom Burton & Co.**: The 2021 biotech financing year in review and look ahead to 2022 (recovery)
- *Café Croissant* with **Anges Québec**: Angels' role in our biotechs' development
- *Café Croissant* with **IRICoR**: From discovery to commercialization – The story behind EPI TOPEA
- *Café Croissant* with **Fasken**: The Court of Appeal of Quebec rules on the PMPRB's new guidelines – impacts, consequences, and issues surrounding this important decision
- *Café Croissant* with **Levoyia**: An animal health research project to accelerate the growth of your human health business
- *Café Croissant* with **Paraza**: A life sciences company's journey from overcoming obstacles to finding success
- *Café Croissant* with **CARTaGENE**: Need access to a databank of Quebec patients? Look no further than CARTaGENE!
- *Café Croissant* with **Robic**: Legislative changes regarding the protection of personal data

SAVINGS AND OPERATIONAL ADVANTAGES

With power in numbers, BIOQuébec can negotiate agreements that benefit its members, its partners, and the association itself. In 2022, more than twenty different services were offered by fifteen or so partners ranging from operational to business development and communications.



FINANCIAL 20 SUMMARY 22

The following balance sheet as of December 31, 2022 and the statement of operations for the year ended December 31, 2022 are provided for information purposes only. They are not intended to replace BIOQuébec's unaudited financial statements, which are available upon request.

BIOQuébec's financial statements as of December 31, 2022 were subject to a review engagement by Blain, Joyal, Charbonneau S.E.N.C.R.L. Professional Chartered Accountants, and an unmodified opinion was issued for those statements.

STATEMENT OF OPERATIONS

FOR THE YEAR ENDED DECEMBER 31, 2022

(unaudited)

	2022	2021
REVENUES	\$	\$
Activities	100,592	59,520
Membership fees	514,465	442,681
Sponsorships	5,000	-
Other income	4,045	13,520
Royalties	19,027	20,200
Sub-lease revenue	-	800
COVID-19 subsidy programs	12,507	25,630
LSHT network	73,115	152,251
	728,751	714,602
EXPENSES		
Activities	87,596	84,627
General administrative expenses	451,188	387,065
Memberships and subscriptions	25,000	25,000
Amortization of capital assets	1,118	382
Amortization of intangible assets	54,747	34,113
Amortization of deferred contributions relating to tangible assets	(29,480)	(8,250)
LSHT network	68,115	105,810
	658,284	628,747
EXCESS OF REVENUES OVER EXPENSES	70,467	85,855
EXCESS OF REVENUES OVER EXPENSES EXCLUDING THE LSHT NETWORK	65,467	39,414

BALANCE SHEET

AS OF DECEMBER 31, 2022
(unaudited)

BALANCE SHEET

	2022	2021
	\$	\$
ASSETS		
Short-term		
Cash	280,153	363,299
Receivables	40,981	42,233
Prepaid fees	14,644	4,186
Security deposit	-	2,000
	355,778	411,718
Tangible fixed assets	3,967	722
Intangible assets	68,765	77,105
	408,510	489,545
LIABILITIES		
Short-term		
Accounts payable	46,588	65,156
Deferred contributions	74,882	199,879
Payments on long-term debt	40,000	-
	161,470	265,035
Long-term debt	-	40,000
Deferred contributions related to intangible assets	19,813	27,750
	181,283	332,785
NET ASSETS		
Net assets invested in capital assets	52,919	50,077
Unrestricted net assets	174,308	106,683
	227,227	156,760
	408,510	489,545

2022-2024 STRATEGIC PLAN

The implementation of BIOQuébec's strategic plan continued throughout the year with the aim of promoting the biotechnology and life sciences sector and making Quebec one of the key stakeholders on the international stage.

BIOQuébec has used its influential leadership, productivity, adaptability, and sense of unity and collaboration to protect its members' interest during its interactions with political representatives and other stakeholders, highlight biosciences' role and contribution, create critical activities for its members, and support them in their growth.

BIOQuébec's Strategic Plan Is Based on These Four Pillars:

A Quebec-based positioning in life sciences focused on translational and industrial R&D in human health: an effective and stable association that produces successes which attract stakeholders from other parts of the human health chain.

A vocation focused on defending its members' shared interests: an association with a proactive and adaptable approach to its strategic positioning, known for its influential leadership and for being a strong partner in raising awareness.

A propensity to foster interrelationships, a catalyst for development and networking, and an executive-level convergence hub: an association with a people-first, collaborative approach that offers privileged access to governments.

A sustainable model focused on creating value for the organization, its members, and society: an autonomous and independent association with an organic development approach for the short and long term and varied, partly-recurring sources of revenue.

BIOQuébec's activities and actions in 2022 were firmly rooted in this vision, and they will continue in a similar manner in the future!

You can access [the strategic plan here](#) (in French only).



BIOQUÉBEC

The Quebec Bio-Industries and Life Sciences Business Network



In 2022, BIOQuébec had the opportunity to transform itself through various stages that allowed it to progress and expand into new situations. Filled with hope, we strive to be fluid like water and solid like ice so we can sublimate like vapour droplets as we travel towards new horizons in 2023.